BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

  • Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 9:00 a.m. ET.

  • Bank of America 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 1:40 p.m. ET.

  • 2025 RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 21, 2025, at 3:05 p.m. ET.



Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on .

BCRXW

Contact:

John Bluth





EN
30/04/2025

Underlying

BCRXBioCryst Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

Wedbush Research
  • Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ACRS ACLARIS THERAPEUTICS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
KNSA KINIKSA PHARMACEUTICALS
ORIC ORIC PHARMACEUTICALS
VRDN VIRIDIAN THERAPEUTICS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
GLUE MONTE ROSA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
CMPX COMPASS THERAPEUTICS
MLTX MOONLAKE IMMUNOTHERAPEUTICS
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
SGMT SAGIMET BIOSCIENCES INC
ORKA ORUKA THERAPEUTICS INC
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
12/18/25 December 18, 2025 1 EN
David Nierengarten ... (+9)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
BCRX BIOCRYST PHARMACEUTICALS INC.
ACRS ACLARIS THERAPEUTICS INC.
WVE WAVE LIFE SCIENCES
KNSA KINIKSA PHARMACEUTICALS
ORIC ORIC PHARMACEUTICALS
VRDN VIRIDIAN THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
CMPX COMPASS THERAPEUTICS
MLTX MOONLAKE IMMUNOTHERAPEUTICS
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
ORKA ORUKA THERAPEUTICS INC
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
12/18/25 December 18, 2025 1 EN
Wedbush Research
  • Wedbush Research
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ARDX ARDELYX INC
WVE WAVE LIFE SCIENCES
FMCC FEDERAL HOME LOAN MORTGAGE CORPORATION
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
NATL NCR ATLEOS CORPORATION
DBD DIEBOLD NIXDORF INCORPORATED
12/12/25 December 12, 2025 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
BCRX BIOCRYST PHARMACEUTICALS INC.
12/12/25 December 12, 2025 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired employees stock options to purchase an aggregate of 57,100 shares, and restricted stock units (RSUs) covering an aggregate of 46,400 shares, of BioCryst common stock. The options and RSUs were granted as of December 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were grant...

December 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch